TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17264717

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in oxygen (8 l/min) via a prefilled circuit, end‐tidal sevoflurane maintained at 4%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vital capacity technique with similar anesthesia protocol as Group A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hyperventilation with similar anesthesia protocol as Group A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: End‐tidal sevoflurane maintained at 2% with similar anesthesia protocol as Group A
Number of subjects: 40
Study: 15117576

Group type: EXPERIMENTAL
Intervention: Guardian Continuous Monitoring System (Alert group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 12516956

Group type: EXPERIMENTAL
Intervention: tolterodine
Number of subjects: 1077
Study: 9619190

Group type: EXPERIMENTAL
Intervention: Young subjects (18-30 years)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Older subjects (62-79 years)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 32
Study: 7710345

Group type: EXPERIMENTAL
Intervention: Intraoperative choledochoscopic electrohydraulic lithotripsy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transduodenal sphincteroplasty
Number of subjects: 10
Study: 2717651

Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (Efamol) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 519632

Group type: EXPERIMENTAL
Intervention: alpha‐methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rubidium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tryptophan‐benserazide
Number of subjects: 0
Study: 30964526

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU/d; n=251)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo (n=166)
Number of subjects: 417
Study: 28911070

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CET/RT (Arm B2)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT or CET/RT
Number of subjects: 414

Group type: COMPARATOR
Intervention: Concomitant treatment alone with CCRT (Arm A1)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Concomitant treatment alone with CET/RT (Arm A2)
Number of subjects: 414
Study: 25580989

Group type: EXPERIMENTAL
Intervention: 0.38% ropivacaine continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.9% saline continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 0.38% ropivacaine CWI in laparotomy subgroup
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.9% saline CWI in laparotomy subgroup
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 0.38% ropivacaine CWI in laparoscopy subgroup
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.9% saline CWI in laparoscopy subgroup
Number of subjects: 67
Study: 23663813

Group type: EXPERIMENTAL
Intervention: Seattle Heart Failure Model (SHFM) score increase by 1 unit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SHFM scores of 1 or 2
Number of subjects: 0
Study: 21425884

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system 10-30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo transdermal system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system
Number of subjects: 0
Study: 18417466

Group type: EXPERIMENTAL
Intervention: Antipsychotic cotreatment
Number of subjects: 1229
Study: 17055302

Group type: EXPERIMENTAL
Intervention: Thrombin-soaked gel foam
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Compressed gas lavage
Number of subjects: 71

Group type: COMPARATOR
Intervention: Saline solution lavage with sponge drying
Number of subjects: 71
Study: 16613264

Group type: EXPERIMENTAL
Intervention: Fuzheng Quxie granule (FQG)
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 1402
Study: 12930196

Group type: EXPERIMENTAL
Intervention: 30 Hz vibration frequency
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 40 Hz vibration frequency
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 Hz vibration frequency
Number of subjects: 16

Group type: COMPARATOR
Intervention: No vibrations
Number of subjects: 16
Study: 10232417

Group type: EXPERIMENTAL
Intervention: Simulated altitude of 8,000 m
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arrival at 5,000 m
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arrival at 8,000 m
Number of subjects: 8
Study: 8934481

Group type: EXPERIMENTAL
Intervention: Immobilization with the arm tied to the torso for three to four weeks after reduction
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Use of a sling, discontinued after patient comfort
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Immobilization for various durations
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Patients aged 12-22 years
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Patients aged 23-29 years
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Patients aged 30-40 years
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Patients with at least two recurrences during the first two or five years
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Radiographs showing evident Hermodsson (Hill-Sachs) lesion
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Radiographs at ten-year follow-up
Number of subjects: 245
Study: 2010899

Group type: EXPERIMENTAL
Intervention: Three-day diet containing greater than 150 g/d of carbohydrate (group I)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal dietary pattern without dietary preparation (group II)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 37
Study: 6121766

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg buspirone hydrochloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg buspirone hydrochloride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31819401

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 0

Group type: COMPARATOR
Intervention: FF/VI
Number of subjects: 0

Group type: COMPARATOR
Intervention: UMEC/VI
Number of subjects: 0
Study: 27422154

Group type: EXPERIMENTAL
Intervention: 0.3mg rhTSH stimulation before radioiodine therapy (group I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group without stimulation (group II)
Number of subjects: 32
Study: 25856740

Group type: EXPERIMENTAL
Intervention: Emotion-regulation therapy combined with cognitive group therapy ('Before and beyond')
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal individual treatment
Number of subjects: 71
Study: 24080287

Group type: EXPERIMENTAL
Intervention: Active Hip Abduction (AHAbd) test
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Active Straight Leg Raise (ASLR) test
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control subjects during AHAbd and ASLR tests
Number of subjects: 34
Study: 21212432

Group type: EXPERIMENTAL
Intervention: Rituximab in combination with fludarabine and cyclophosphamide (FC)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 1369
Study: 19519312

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study: 17962427

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 3.0 microg/kg
Number of subjects: 42
Study: 15465578

Group type: EXPERIMENTAL
Intervention: rTMS applied to the left prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rTMS applied to the right prefrontal cortex
Number of subjects: 0
Study: 11675939

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 429

Group type: COMPARATOR
Intervention: Diuretic (trichlormethiazide)
Number of subjects: 429
Study: 9133508

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 0
Study: 7701044

Group type: EXPERIMENTAL
Intervention: Cocaethylene (0.25 mg/kg cocaethylene base)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cocaine (0.25 mg/kg cocaine base)
Number of subjects: 6
Study: 2959665

Group type: EXPERIMENTAL
Intervention: Cobe CML oxygenator
Number of subjects: 19

Group type: COMPARATOR
Intervention: Shiley S‐100 bubble oxygenator
Number of subjects: 19
Study: 31170036

Group type: EXPERIMENTAL
Intervention: Error ABF
Number of subjects: 4

Group type: COMPARATOR
Intervention: Full ABF
Number of subjects: 4
Study: 27720499

Group type: EXPERIMENTAL
Intervention: Home-based caregiver-training program
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 129
Study: 25794203

Group type: EXPERIMENTAL
Intervention: SGB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 20
Study: 23275278

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 1040
Study: 22230406

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy with cisplatin and gemcitabine plus immunotherapy with PBMC and rIL-2
Number of subjects: 82

Group type: COMPARATOR
Intervention: Neo-adjuvant chemotherapy with cisplatin and gemcitabine
Number of subjects: 82
Study: 19799138

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16924981

Group type: EXPERIMENTAL
Intervention: Repair (n=20)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sealing of defective margins (n=23)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Refurbishing (n=23)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Replacement (n=23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No-treatment (n=24)
Number of subjects: 45
Study: 15689090

Group type: EXPERIMENTAL
Intervention: Two-dose varicella vaccine
Number of subjects: 186

Group type: COMPARATOR
Intervention: One-dose varicella vaccine
Number of subjects: 186
Study: 14622777

Group type: EXPERIMENTAL
Intervention: 4030W92 (25 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9444683

Group type: EXPERIMENTAL
Intervention: Therapeutic community
Number of subjects: 694

Group type: COMPARATOR
Intervention: Community residences
Number of subjects: 694
Study: 7624492

Group type: EXPERIMENTAL
Intervention: Levetiracetam (pyrrolidine derivative) as an antiepileptic concomitant drug
Number of subjects: 0
Study: 2612406

Group type: EXPERIMENTAL
Intervention: Dibonis
Number of subjects: 4

Group type: COMPARATOR
Intervention: Diabinese
Number of subjects: 4
Study: 140824

Group type: EXPERIMENTAL
Intervention: Ro 11-1430 (0.1% lotion)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Vitamin A acid (0.05% lotion)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo (lotion alone)
Number of subjects: 257
Study: 31495658

Group type: EXPERIMENTAL
Intervention: Multimodality stimulation combined with standard physiotherapy (therapy group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard physiotherapy alone (control group)
Number of subjects: 12
Study: 31640153

Group type: EXPERIMENTAL
Intervention: Arm 1 (supplementation before conception)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Arm 2 (supplementation late 1st trimester)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Arm 3 (usual care)
Number of subjects: 1465
Study: 27794487

Group type: EXPERIMENTAL
Intervention: Direct skill training (n=22, 10 sessions as adjunct to usual inpatient rehabilitation)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Guided training (n=21, same dose)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Guided training
Number of subjects: 43
Study: 25822465

Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement
Number of subjects: 4516

Group type: COMPARATOR
Intervention: Anterior cervical decompression and fusion
Number of subjects: 4516
Study: 23335675

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 5 years
Number of subjects: 184460

Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day for 5 years
Number of subjects: 184460
Study: 21076131

Group type: EXPERIMENTAL
Intervention: Homeopathic consultation
Number of subjects: 83
Study: 20031731

Group type: EXPERIMENTAL
Intervention: Catheter-based local delivery of fluid paclitaxel after bare metal stent implantation (group I)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Bare metal stent implantation (group II)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (group III)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Catheter-based local delivery of fluid paclitaxel (group I)
Number of subjects: 204
Study: 17314736

Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day (RLX)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day + 17beta‐estradiol 1 mg/day (RLX + E)
Number of subjects: 123
Study: 14752071

Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidines for 1 year
Number of subjects: 5233
Study: 11096006

Group type: EXPERIMENTAL
Intervention: Mupirocin treatment
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Presence of > or = 2 positive body sites
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Previous receipt of fluoroquinolone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Low-level mupirocin resistance
Number of subjects: 102
Study: 8956398

Group type: EXPERIMENTAL
Intervention: Subarachnoid neostigmine 75 micrograms (1.5 mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received 1.5 mL subarachnoid saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received 15 mg (3 mL) of hyperbaric bupivacaine 0.5%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neostigmine group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 1414563

Group type: EXPERIMENTAL
Intervention: Personal empowerment program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 4055985

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg m‐CPP, orally
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28851788

Group type: EXPERIMENTAL
Intervention: Regional transarterial hypothermic infusion (cold saline at 15°C) administered through a microcatheter in the ipsilateral internal carotid artery after thrombectomy when no improvement in NIHSS score is observed.
Number of subjects: 7
Study: 25361617

Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 = 0.11)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoxia (FiO2 = 0.21)
Number of subjects: 15
Study: 23588685

Group type: EXPERIMENTAL
Intervention: Strawberry-flavored lozenge (Strepsils® strawberry sugar free)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Orange-flavored lozenge (Strepsils® orange with vitamin C)
Number of subjects: 102
Study: 21826881

Group type: EXPERIMENTAL
Intervention: Bipolar TURP (Gyrus electro surgical system)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Open prostatectomy (OPSU)
Number of subjects: 140
Study: 18679613

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whey protein isolate (WPI)
Number of subjects: 16
Study: 17093155

Group type: EXPERIMENTAL
Intervention: Exercise training (EX group; n = 18)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR group; n = 18)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy lifestyle (HL control group; n = 10)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Exercise training (EX group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy lifestyle (HL control group)
Number of subjects: 46
Study: 14687901

Group type: EXPERIMENTAL
Intervention: Allopurinol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzbromarone treatment
Number of subjects: 0
Study: 11518893

Group type: COMPARATOR
Intervention: Single dose of 150 mg fluconazole
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Two sequential doses of 150 mg fluconazole given 3 days apart
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Two-dose fluconazole regimen
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Two doses of fluconazole
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 556
Study: 9028935

Group type: EXPERIMENTAL
Intervention: Rearranged TEL gene group (27 patients)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Germline TEL group (77 patients)
Number of subjects: 104
Study: 8402802

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Chelon‐Fil‐Espe)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Composite (Silux)
Number of subjects: 10
Study: 3947414

Group type: EXPERIMENTAL
Intervention: 750-rad lymphoid irradiation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2,000-rad lymphoid irradiation
Number of subjects: 20
Study: 3276469

Group type: EXPERIMENTAL
Intervention: Combined oral and parenteral antimicrobial prophylaxis
Number of subjects: 119

Group type: COMPARATOR
Intervention: Parenteral antimicrobial prophylaxis
Number of subjects: 119
Study: 29332419

Group type: EXPERIMENTAL
Intervention: EnergyPod™
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SleepWing™
Number of subjects: 0
Study: 28910662

Group type: EXPERIMENTAL
Intervention: Three-day clinical skills refresher course directed by nurse instructors
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 26412215

Group type: EXPERIMENTAL
Intervention: Mixed nuts (30 g/d) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23635898

Group type: EXPERIMENTAL
Intervention: Combined written and verbal instructions
Number of subjects: 39

Group type: COMPARATOR
Intervention: Written instructions only
Number of subjects: 39
Study: 21590739

Group type: EXPERIMENTAL
Intervention: High-protein drink containing 30g of whey protein (n=109)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo drink containing 2.1g of protein (n=110)
Number of subjects: 219
Study: 19100110

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cutting balloon angioplasty followed by bare metal stents (CBA + BMS)
Number of subjects: 101
Study: 16540953

Group type: COMPARATOR
Intervention: Oxygen catheter (6 L/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: T-piece system (12 L/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CPAP system (10 cm H2O, 12 L/min)
Number of subjects: 20
Study: 12880400

Group type: EXPERIMENTAL
Intervention: Carbon fibre reinforced carbon (CFRC) endodontic post cemented with a composite luting agent
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional prefabricated post (wrought precious alloy) cemented with zinc phosphate
Number of subjects: 18
Study: 11025363

Group type: EXPERIMENTAL
Intervention: THL 120 mg t.i.d.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 8
Study: 8881951

Group type: EXPERIMENTAL
Intervention: Finasteride treatment for a minimum of 9 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Finasteride treatment
Number of subjects: 20
Study: 1411281

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4056780

Group type: EXPERIMENTAL
Intervention: MOMMY AND I ARE ONE (subliminal exposure with pictures)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: MOMMY AND I ARE ONE (subliminal exposure without pictures)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Other experimental stimuli (MOMMY IS ALWAYS WITH ME, MOMMY FEEDS ME WELL, I CANNOT HURT MOMMY)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control stimulus (PEOPLE ARE WALKING)
Number of subjects: 128
Study: 30354562

Group type: EXPERIMENTAL
Intervention: DASH/SRD (Dietary Approaches to Stop Hypertension meals; 1500 mg sodium/d)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: DASH/SRD
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 27535783

Group type: EXPERIMENTAL
Intervention: Ibandronate 150mg/month
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Risedronate 35mg/week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Alendronate 70mg/week
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (25 healthy premenopausal women, mean age 37)
Number of subjects: 62
Study: 24958563

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bifidobacteria (highest tertile)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bifidobacteria changes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Syringic acid and 4‐hydroxybenzoic acid changes
Number of subjects: 9
Study: 22678051

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (237 ml, 182 mg caffeine)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Decaffeinated coffee (237 ml, 4 mg caffeine)
Number of subjects: 106
Study: 20546197

Group type: EXPERIMENTAL
Intervention: Modified sequential three-step empirical therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Primary sequential three-step empirical therapy
Number of subjects: 240
Study: 18509926

Group type: EXPERIMENTAL
Intervention: Complexes of physical and respiratory exercises according to developed medical technology
Number of subjects: 177